What the FDA labels say about taking them together
Cyclosporine and pitavastatin
Pitavastatin's FDA label of March 31, 2026 names cyclosporine in its contraindications section; cyclosporine's label does not name pitavastatin itself but warns about its class (Statins). The pitavastatin label: “Cyclosporine significantly increases pitavastatin exposure and increases the risk of myopathy and rhabdomyolysis.”
Check it at the source: the cyclosporine FDA label on DailyMed (effective August 10, 2026, Novartis Pharmaceuticals Corporation); the pitavastatin FDA label on DailyMed (effective March 31, 2026, Kowa Pharmaceuticals America, Inc.).
What does the cyclosporine label say about pitavastatin?
Cyclosporine's label does not name pitavastatin itself; it warns about its class (Statins):
Cyclosporine label, drug interactionsCyclosporine may reduce the clearance of digoxin, colchicine, prednisolone, HMG-CoA reductase inhibitors (statins), aliskiren, bosentan, dabigatran, repaglinide, NSAIDs, sirolimus, etoposide, and other drugs.
Cyclosporine label, drug interactionsHMG-CoA Reductase Inhibitors (Statins) Literature and postmarketing cases of myotoxicity, including muscle pain and weakness, myositis, and rhabdomyolysis, have been reported with concomitant administration of cyclosporine with lovastatin, simvastatin, atorvastatin, pravastatin, and rarely fluvastatin.
Source: FDA drug label (Neoral), Novartis Pharmaceuticals Corporation, effective August 10, 2026 (SPL set 94461af3-11f1-4670-95d4-2965b9538ae3), via openFDA; the full label on DailyMed
What does the pitavastatin label say about cyclosporine?
Pitavastatin label, contraindicationsCONTRAINDICATIONS LIVALO is contraindicated in the following conditions: Concomitant use of cyclosporine [see Drug Interactions (7) ].
Pitavastatin label, drug interactionsCyclosporine Clinical Impact: Cyclosporine significantly increases pitavastatin exposure and increases the risk of myopathy and rhabdomyolysis. Intervention: Concomitant use of cyclosporine with LIVALO is contraindicated [see ].
Pitavastatin label, warnings and precautionsSteps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis LIVALO is contraindicated in patients taking cyclosporine and not recommended in patients taking gemfibrozil [see Contraindications (4) and Drug Interactions (7) ].
Source: FDA drug label (Zypitamag, NDA208379), Medicure International Inc, effective December 3, 2025 (SPL set c8c50e03-5cb8-43f4-bdef-8edd12f1945f), via openFDA
Source: FDA drug label (Livalo), Kowa Pharmaceuticals America, Inc., effective March 31, 2026 (SPL set 44dcbf97-99ec-427c-ba50-207e0069d6d2), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cyclosporine | Pitavastatin | |
|---|---|---|
| Labeled for | Organ transplant rejection, Rheumatoid arthritis | High cholesterol |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $1.04 per unit 0.05% eye emulsion | $0.954 per tablet 2 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once